Contributions
Abstract: P1116
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - 25 Biomarkers
Background and goals: The long-term prognosis of relapsing-remitting multiple sclerosis (RRMS) is unpredictable. Neurofilament light chain (NfL) is a promising biomarker to predict long-term outcome.
No studies have examined changes in cerebrospinal fluid (CSF) levels of NfL after treatment with dimethyl fumarate (DMF).
Method: CSF was collected from newly diagnosed patients with clinically definite relapsing remitting MS (RRMS) (n=37) and healthy subjects (HS, n=16). In a subgroup of RRMS patients (n=14), CSF was also collected after 12 months of treatment with DMF. NfL concentration was analyzed with electro-chemiluminescence immunoassay (MesoScale Discovery). The study was approved by the Local Committee on Health Research Ethics and the Danish Data Protection Agency.
Results: The mean age HS and MS patients was respectively 43.1± 10.9 years and 34.1± 8.7 years
(p< 0.05). EDSS at baseline was 1.3±0.8, and EDSS at 1-year follow up was 1.8±0.81 (p< 0.05). NfL test-retest demonstrated stable results with a correlation coefficient (r) of 0.99 (p< 0.0001). Pre-treatment NfL concentration in the CSF was higher in MS patients compared to HS (mean 1500±216.0 pg/ml versus 255±23.3 pg/ml, p< 0.001). NfL levels showed no correlation with time after relapse (Spearman r: 0.13, n.s.), age (Spearman r: 0.02, n.s.) or EDSS (Spearman r: 0.20, n.s.). NfL concentration in DMF treated patients was 1988±470.5 pg/ml before treatment, and 606±156.8 pg/ml after one year treatment; this equals a mean reduction of 1382±449.0 pg/ml (p< 0.01) and an average reduction of 58.9%. NfL concentration normalized in 64.3 % of the patients, decreased but was above normal in 21.4% of the patients, and was stable in 14.3% of the patients.
Conclusion: One year treatment with DMF reduces NfL levels in patients with treatment-naïve early RRMS, and returns NfL levels to normal levels in about two out of three patients.
Disclosure:
Dr. Sejbaek has served on scientific advisory boards, received support for congress participation, received speaker honoraria, and received research support from Biogen, Merck-Serono, Lundbeck, and Novartis.
Dr Nielsen has served on scientific advisory boards, received support for congress participation, received speaker honoraria, and received research support from Biogen, Merck-Serono, Lundbeck, and Novartis.
MSc Martin has nothing to disclosure
MSc Elkjaer has nothing to disclosure
Dr. Ravnborg has nothing to disclosure
Dr. Illes has served on scientific advisory boards, served as a consultant, received support for congress participation, received speaker honoraria, and received research support from Biogen, Merck-Serono, Sanofi-Genzyme, Lundbeck, and Novartis.
Abstract: P1116
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - 25 Biomarkers
Background and goals: The long-term prognosis of relapsing-remitting multiple sclerosis (RRMS) is unpredictable. Neurofilament light chain (NfL) is a promising biomarker to predict long-term outcome.
No studies have examined changes in cerebrospinal fluid (CSF) levels of NfL after treatment with dimethyl fumarate (DMF).
Method: CSF was collected from newly diagnosed patients with clinically definite relapsing remitting MS (RRMS) (n=37) and healthy subjects (HS, n=16). In a subgroup of RRMS patients (n=14), CSF was also collected after 12 months of treatment with DMF. NfL concentration was analyzed with electro-chemiluminescence immunoassay (MesoScale Discovery). The study was approved by the Local Committee on Health Research Ethics and the Danish Data Protection Agency.
Results: The mean age HS and MS patients was respectively 43.1± 10.9 years and 34.1± 8.7 years
(p< 0.05). EDSS at baseline was 1.3±0.8, and EDSS at 1-year follow up was 1.8±0.81 (p< 0.05). NfL test-retest demonstrated stable results with a correlation coefficient (r) of 0.99 (p< 0.0001). Pre-treatment NfL concentration in the CSF was higher in MS patients compared to HS (mean 1500±216.0 pg/ml versus 255±23.3 pg/ml, p< 0.001). NfL levels showed no correlation with time after relapse (Spearman r: 0.13, n.s.), age (Spearman r: 0.02, n.s.) or EDSS (Spearman r: 0.20, n.s.). NfL concentration in DMF treated patients was 1988±470.5 pg/ml before treatment, and 606±156.8 pg/ml after one year treatment; this equals a mean reduction of 1382±449.0 pg/ml (p< 0.01) and an average reduction of 58.9%. NfL concentration normalized in 64.3 % of the patients, decreased but was above normal in 21.4% of the patients, and was stable in 14.3% of the patients.
Conclusion: One year treatment with DMF reduces NfL levels in patients with treatment-naïve early RRMS, and returns NfL levels to normal levels in about two out of three patients.
Disclosure:
Dr. Sejbaek has served on scientific advisory boards, received support for congress participation, received speaker honoraria, and received research support from Biogen, Merck-Serono, Lundbeck, and Novartis.
Dr Nielsen has served on scientific advisory boards, received support for congress participation, received speaker honoraria, and received research support from Biogen, Merck-Serono, Lundbeck, and Novartis.
MSc Martin has nothing to disclosure
MSc Elkjaer has nothing to disclosure
Dr. Ravnborg has nothing to disclosure
Dr. Illes has served on scientific advisory boards, served as a consultant, received support for congress participation, received speaker honoraria, and received research support from Biogen, Merck-Serono, Sanofi-Genzyme, Lundbeck, and Novartis.